China Resources Pharmaceutical Group Limited (CHINARES PHARMA) reported 1H26 revenue of RMB134.46 billion, a 2.0 % increase year-on-year. Gross profit edged up 0.1 % to RMB21.53 billion, while overall gross margin slipped 0.3 percentage points to 16.0 %.\n\nNet profit came in at RMB5.02 billion, down 0.6 % from 1H25, but profit attributable to equity shareholders rose 5.3 % to RMB2.19 billion, lifting basic EPS to RMB0.35. The board declared an interim dividend of RMB0.087 per share (HK$0.1006), 21 % higher than last year’s interim payout.\n\nSegment performance showed Manufacturing contributing 16.2 % of group revenue (RMB24.44 billion, ‑1.5 % YoY) with a 60.3 % gross margin, up 1.0 percentage point. Distribution remained the core driver at 79.1 % of revenue (RMB110.99 billion, +2.5 % YoY) and delivered a 5.7 % gross margin. Retail and other operations generated RMB6.34 billion, up 14.9 %, with a 6.3 % margin.\n\nCash flow from operations reached RMB1.42 billion (1H25: RMB1.53 billion). Net debt to equity rose to 52.0 % from 47.4 % at year-end 2025. Cash and cash equivalents stood at RMB15.62 billion, while total borrowings amounted to RMB59.39 billion; 89.1 % of borrowings mature within one year.\n\nManagement highlighted R&D spending of RMB1.36 billion (+8.7 % YoY), two state key laboratories, and 359 pipeline projects, including 130 new drugs. The group advanced its synthetic-biology programme, completed acquisitions of Dong-E-E-Jiao Jilin and Nanjing Xinbai, and progressed integration of Tasly Pharmaceutical. Export revenue from manufacturing reached approximately RMB700 million.\n\nDistribution initiatives focused on in-depth marketing, high-standard compliance, and expansion of medical-device services, which grew 14 % YoY to RMB20.5 billion in revenue. Retail operations were strengthened through professional pharmacy expansion; DTP sales rose 28.6 % to roughly RMB4.83 billion.\n\nESG performance remained strong with an MSCI ESG rating of A and a Wind ESG rating of AA. Rooftop solar projects with 12.3 MW capacity are expected to reduce emissions by about 7,500 tonnes annually.\n\nPost-period, subsidiary CR Double-Crane signed a deal to acquire 23.5 % of Lier Chemical for RMB5.66 billion, aiming to build a leading synthetic-biology platform. The transaction awaits completion.\n\nManagement reiterated its “15th Five-Year” strategy: deepen innovation, expand in biologics, blood products and medical devices, pursue disciplined M&A, and enhance digital and green capabilities, while maintaining prudent liquidity management.